Skip to main content

Table 2 SPHK1 and S1P inhibitors in clinical development as anti-cancer therapies

From: Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer

Agent Mechanism Stage of Clinical Development References
Safingol SPHK1 inhibitor Demonstrated safety in combination with cisplatin in Phase I trial in solid tumours [43, 46, 47]
Fingolimod S1P receptor antagonist Licenced for use in multiple sclerosis. No data on clinical use in cancer [29, 30, 44]
Sonepcizumab Humanised S1P neutralising monoclonal antibody Demonstrated safety in Phase I trial in solid tumours [48, 49]